Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
Patients
HCPs
Worldwide
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts & Japan offices
History
Worldwide Offices
Executive Leadership
Positions
Takeda Global Headquarters
Life at Takeda
Design Concept
Where we work
Corporate Philosophy
Our People
Values and Corporate Governance
Corporate Governance
Risk & Crisis Management
Global Ethics & Compliance / Global Code of Conduct
Transparency Disclosures
From the CEO
Contact Us
Celebrating the grand opening of Takeda Global Headquarters
LEARN MORE
What We Do
Our Business
We will become a global, values-based, R&D-driven, biopharmaceutical leader
Learn more
Research & Development
Ecosystem for Health Innovation
Our Pipeline
Clinical Trials
Investigator Initiated Research
Takeda Ventures, Inc.
Areas of Focus
Oncology
Rare Diseases
Neuroscience
Gastroenterology
Plasma-Derived Therapies
Vaccines
Alliances & Partnerships
Partnering with Takeda
Takeda Digital Ventures
Our Products
Manufacturing
Innovation Story
Access to Medicines
Our Approach and Our Position
Hear from Patients
Driving Impact with Partners
Pre- Approval Access
Suppliers
Sustainable Procurement
Supplier Code of Conduct
Supplier Diversity
Pharmaceutical Supply Chain Initiative
Supplier Qualification & Due Diligence
Shire Supplier Information
Takeda Supplier Solutions Portal
Supplier Registration Process via Ariba Commerce Cloud
T-CiRA
About T-CiRA
Leaders Message
What we do
Portfolios
Project members
Inside T-CiRA
Research Achievements
We focus on our core therapeutic areas.
LEARN MORE
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
Takeda Leaders Highlight Continued Business Transformation at Virtual J.P. Morgan Healthcare Conference
A Look Inside Takeda’s Wave 1 Pipeline
Quality at Takeda
The Key Elements at the Heart of Our Innovation
Caring
New In Their Shoes Experience Simulates Short Bowel Syndrome with Intestinal Failure
Shifting paradigms of COVID-19 reflections from the 75th UN General Assembly
Improving Access to Healthcare in Remote Communities
Harnessing the Power of People to Transform Health Care
Shared Knowledge for a Better Life for All
Heritage
Keys to Aging Gracefully
Harnessing the power of people to transform health care
LEARN MORE
Corporate Responsibility
Takeda's CSR
Takeda is committed to addressing the world’s biggest challenges to sustainable development over the long term.
LEARN MORE
Programs in Action
Takeda Chair in Global Child Health
Takeda Initiative for the Global Fund
Global CSR Program
Apply for Funding
Frequently Asked Questions
Leaders Driving Change
Sustainable Value Report
Introduction
Patient
People
Planet
Governance
Appendix
Human Rights
Labor
Environment
Commitment to Carbon Neutrality
Emission Reduction Targets
Anti-Corruption
TAKEDA LIFE THEATER
Partner with our Global CSR Program
LEARN MORE
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
Statements
In the News
Featured Topics
Corporate Materials
Social Media
Message from the CEO
News Releases
Enter
All
Last 12 months
2021
2020
2019
2018
2017
2016
2015
2014
March 2021
March 3, 2021
3/3/2021
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
February 2021
February 26, 2021
2/26/2021
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
February 24, 2021
2/24/2021
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
February 12, 2021
2/12/2021
Takedas Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory With or Without Resistance Cytomegalovirus Infection Disease
February 10, 2021
2/10/2021
Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease
February 4, 2021
2/4/2021
Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)
February 4, 2021
2/4/2021
Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS
February 3, 2021
2/3/2021
Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements
February 1, 2021
2/1/2021
Takeda Completes Sale of TachoSil® to Corza Health
1
2
3
4
5
TOP